Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
- 1 April 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (4) , 1522-1524
- https://doi.org/10.1128/aac.00074-08
Abstract
PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.Keywords
This publication has 7 references indexed in Scilit:
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLoS Medicine, 2006
- Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2006
- Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2005
- Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- The Need for New Drugs against TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisNature, 2000